India's first mRNA-based Covid-19 vaccine candidate HGCO19 by Gennova Biopharmaceuticals Ltd has been granted approval for phase 2/3 clinical trials, the department of biotechnology (DBT) said on Tuesday.

The Pune-based biotechnology company had submitted the interim clinical data of the vaccine's phase 1 study to the central drugs standard control organisation, it said.The vaccine subject expert committee reviewed the interim phase 1 data and found that the HGCO19 vaccine was safe, tolerable, and immunogenic in the participants of the study.

Leave a Reply

Your email address will not be published. Required fields are marked *